News

November 9, 2018November 9, 2018

FDA Approves Sandoz’s Hyrimoz, Biosimilar to Humira, for Juvenile Arthritis, Other Diseases

News

The U.S. Food and Drug Administration has granted approval to Sandoz’s Hyrimoz (adalimumab-adaz), a biosimilar to Abbvie’s Humira. FDA approval includes indications for seven diseases, including juvenile idiopathic arthritis for ... Read more

November 2, 2018November 2, 2018

Charitable Book is Told Through the Eyes of Critically Ill Children

News

After a chance meeting in a New York City restaurant with a young boy who shared what life was like with brain cancer, Samantha Hasen was moved to raise ... Read more

October 22, 2018October 22, 2018

Amgen Launches Humira Biosimilar, Amgevita, in Markets Across Europe

News

Amgen recently launched Amgevita, a biosimilar to Abbvie’s Humira (adalimumab), in Europe after approval by the European Commission. The therapy will be available in the 28 countries of the European Union, ... Read more

October 19, 2018October 19, 2018

Imraldi, BioSimilar to Humira, Now Available in Europe to Treat JIA, Other Conditions

News

Imraldi, an adalimumab biosimilar of reference product Humira from AbbVie, will now be available to patients in the European Union, Samsung Bioepis the therapy’s maker, recently announced. In August 2017, the European Commission approved ... Read more

October 8, 2018October 8, 2018

Exercise and Psychological Training May Help to Ease Chronic Pain in Juvenile Arthritis

News

Non-pharmacological treatments, such as psychological and exercise-based interventions, may be a viable way of easing pain in children and teenagers with pediatric rheumatic disease, also known as juvenile arthritis, a ... Read more

October 1, 2018October 1, 2018

Humira Biosimilar Hulio Granted Marketing Authorization in Europe for JIA, Others

News

Mylan and Fujifilm Kyowa Kirin Biologics were granted marketing authorization for biosimilar Hulio (adalimumab) by the European Commission for all the indications of its reference product, AbbVie‘s Humira (adalimumab), including ... Read more

September 21, 2018September 21, 2018

FDA Approves Subcutaneous Form of Actemra for Active Systemic Juvenile Idiopathic Arthritis

News

The U.S. Food and Drug Administration (FDA) has approved Genentech’s formulation of Actemra (tocilizumab) by subcutaneous injection for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in children ages 2 and ... Read more

September 10, 2018September 10, 2018

Actemra Shows Sustained Safety, Efficacy in Children with pJIA, Extension Trial Shows

News

Long-term treatment with Actemra (tocilizumab) shows sustained safety and effectiveness in children with polyarticular juvenile idiopathic arthritis (pJIA), according to the results of a Phase 3 clinical trial. The ... Read more

September 7, 2018September 7, 2018

Humira’s Safety in Children With JA, Other Diseases Comparable to That in Adults, Study Suggests

News

The safety profile of Humira (adalimumab) in children with polyarticular juvenile idiopathic arthritis (pJIA), enthesitis-related arthritis, and Crohn’s disease is similar to that in adults, a large analysis of ... Read more

August 31, 2018August 31, 2018

Terry Bradshaw Supports ACR’s ‘Simple Tasks’ Initiative for Rheumatic Disease Care

News

In a nationwide public service announcement, former Pittsburgh Steelers quarterback Terry Bradshaw urges fellow rheumatic disease patients to take the pledge to manage their disease and live well. The ... Read more

Pin It on Pinterest